Annual Report

Overview

The report highlights BioArctic's positive Phase 3 results for lecanemab, regulatory progress and expansion of its project portfolio in 2022. It reports consolidated net revenue of MSEK 228.3, driven largely by milestone and collaboration payments. The workforce increased to 61 employees at year-end as the company built a Nordic commercial organization.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2022
Period: 1 January 2022 – 31 December 2022
Language: English
Pages
File size
Restatement: Disclosed

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services